Sample · Courtiva · Know Who It Affects

Client advisory draft

A draft advisory for each major change, for you to review and send under your own name.

All samples · These samples were built for a real client, a billing company for behavioral health providers. Every company, person, story and number from that client is invented here. Public news, rulings and rules are real and link to their sources.

From Northstead Behavioral BillingClient advisory ยท draft for review

Client advisory draft

A draft advisory for each major change, for the client to review and send to its own customers under its own name

DEA telehealth prescribing flexibilities for controlled substances expire Dec 31, 2026

What is happening

  • Since 2020, DEA has let registered practitioners prescribe Schedule II to V controlled substances by telemedicine without first seeing the patient in person. The current (fourth) extension runs through Dec 31, 2026 and expires at the end of that day.
  • DEA proposed a permanent "special registration" for telemedicine on Jan 17, 2025. The final rule went to White House review on Aug 25, 2026. As of Nov 2, 2026 it was unpublished and its contents are not public.
  • As of Nov 2, 2026 DEA had not announced a fifth extension. Last year the extension came on Dec 30.
  • A separate buprenorphine rule, in effect since Dec 31, 2025, stays in force regardless. It allows up to six calendar months of buprenorphine for opioid use disorder by telemedicine after a documented review of the state prescription monitoring database.
Key dates
  • Aug 25, 2026: final rule entered White House review
  • Dec 31, 2026: current flexibilities expire at end of day
  • Jan 1, 2027: in-person evaluation generally required for new telemedicine controlled-substance prescriptions unless DEA acts
Still unknown
  • Whether DEA will publish the final rule, a fifth extension, or both before Dec 31.
  • What the final rule requires and how long registration will take.
  • State prescribing rules may differ from federal rules and are not covered here.
Steps to consider
  • Pull a list of active patients receiving controlled-substance prescriptions who have never had an in-person evaluation with the prescriber.
  • For those patients, schedule in-person evaluations before Dec 31 where feasible, and document the visit as in person.
  • For buprenorphine patients, confirm each telemedicine start has a documented database review and track the six-month clock.
  • Build a January backup schedule so visits and refills are not cancelled if DEA acts late, and prepare patient communication now.
  • Assign one person to check the Federal Register weekly through Dec 31.

Drafted for the client to review and send to its provider customers under its own name. This advisory summarizes public sources and is not legal advice.

How to hire your first teammate

Pick a teammate and start at Level 2, free for 30 days. No card needed to start. A short intake tells it about your business, and the first delivery arrives within 48 hours.

Not sure which teammate fits? Talk to a coach